Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
Retrieved on:
Monday, November 15, 2021
Cardiology, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Fitness & Nutrition, Science, Clinical Trials, Safety, TKR, Private Securities Litigation Reform Act, Therapy, Thrombosis, Clinical trial, Leadership, SSP, Security (finance), Sumathi Best Television Current Reporting Award, Bristol Myers Squibb, Risk, Anticoagulant, Goal, Instagram, Research, Facebook, Forward-looking statement, Annual report, Leg, YouTube, Twitter, Sodium, Incidence, U.S. Securities and Exchange Commission, VTE, Xia, LinkedIn, Janssen Pharmaceuticals, Pulmonary embolism, Death, Janssen, Juno Therapeutics, Marketing, Patient, Bleeding, Head, Birth control, Pharmaceutical industry, AXIOMATIC-TKR, Milvexian*, the Bristol Myers Squibb/Janssen Collaboration, Bristol Myers Squibb, AXIOMATIC-TKR, MILVEXIAN*, THE BRISTOL MYERS SQUIBB/JANSSEN COLLABORATION, BRISTOL MYERS SQUIBB
Across a 16-fold range of doses, milvexian demonstrated a low risk of major plus CRNM bleeding, with no major bleeds and no dose-response on this composite outcome.
Key Points:
- Across a 16-fold range of doses, milvexian demonstrated a low risk of major plus CRNM bleeding, with no major bleeds and no dose-response on this composite outcome.
- The clear dose efficacy response without increased bleeding provides additional evidence to support our belief in the promise of milvexian.
- The TKR study is the first of two studies to read out from the Phase 2 milvexian program.
- Milvexian is a potential first-in-class oral factor XIa (FXIa) inhibitor (anti-thrombotic) for the prevention and treatment of major thrombotic conditions.